The biotech firm raised its full-year guidance following stronger-than-expected second-quarter earnings and sales.
Amgen raised its 2026 non-GAAP earnings per share guidance to $22.30-$23.50 from $21.70-$23.10 after Q2 results exceeded expectations. The new range tops consensus estimates of $22.35.
Revenue projections for the year were also increased to $38B-$39.4B from $37.1B-$38.5B, above the $37.73B consensus. The company cited strong performance across its portfolio as the driver for the upward revision.
Shares of AMGN were steady in after-hours trading as investors digested the updated outlook.